Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
AstraZeneca
Moodys
Boehringer Ingelheim
Merck

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,420,057

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,420,057 protect, and when does it expire?

Patent 7,420,057 protects ADDYI and is included in one NDA.

This patent has thirty-nine patent family members in thirty countries.

Summary for Patent: 7,420,057
Title:Stable polymorph of flibanserin
Abstract: The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.
Inventor(s): Bombarda; Carlo (Chester, VA), Dubini; Enrica (Milan, IT), Ezhaya; Antoine (Milan, IT), Schneider, legal representative; Margarete (Ingelheim, DE), Schneider; Heinrich (Ingelheim, DE)
Assignee: Boehringer Ingelheim Pharma KG (Ingelheim, DE)
Application Number:11/546,304
Patent Claim Types:
see list of patent claims
Compound; Composition; Process;

Drugs Protected by US Patent 7,420,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sprout Pharms ADDYI flibanserin TABLET;ORAL 022526-001 Aug 18, 2015 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,420,057

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01118593Aug 2, 2001
01130180Dec 19, 2001

International Family Members for US Patent 7,420,057

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 036208   Start Trial
Argentina 077416   Start Trial
Austria 288911   Start Trial
Australia 2002331361   Start Trial
Brazil 0211601   Start Trial
Brazil 122012029907   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Johnson and Johnson
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.